ACRV
HealthcareAcrivon Therapeutics, Inc.
$2.29
$-0.17 (-6.91%)
Jan 5, 2026
Price History (1Y)
Analysis
Acrivon Therapeutics, Inc. is a biotechnology company in the healthcare sector with approximately 75 employees. The company's market capitalization is $72.26 million. The company's financial health is characterized by significant net losses and negative margins. Net income (TTM) was -$81,751,000, while EBITDA and free cash flow were also negative at -$87,654,000 and -$40,886,000, respectively. The gross margin, operating margin, and profit margin were all 0.0%. The return on equity was -50.2%, and the return on assets was -30.9%. Debt to equity ratio is 2.32, with cash of $129.25 million and debt of $2.99 million. The company's valuation metrics are notable for their low price-to-book ratio of 0.56, as well as a negative forward P/E ratio of -1.20. The beta was 1.75, indicating higher volatility relative to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $72.26M
- P/E Ratio
- N/A
- 52-Week High
- $8.00
- 52-Week Low
- $1.05
- Avg Volume
- 708.21K
- Beta
- 1.75
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 75